Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.

Creator(s)

Jonathan B. Wagner, Children's Mercy HospitalFollow
Susan M. Abdel-Rahman, Children's Mercy HospitalFollow
Andrea Gaedigk, Children's Mercy HospitalFollow
R Gaedigk, Children's Mercy HospitalFollow
Geetha Raghuveer, Children's Mercy HospitalFollow
Vincent S. Staggs, Children's Mercy HospitalFollow
Leon Van Haandel, Children's Mercy Hospital
J Steven Leeder, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

5-2020

Identifier

DOI: 10.1111/cts.12749; PMCID: PMC7214659

Abstract

This study investigated the impact of SLCO1B1 genotype on rosuvastatin systemic exposure in hypercholesterolemic children and adolescents. Participants (8-21 years) with at least one allelic variant of SLCO1B1 c.521T>C (521TC, n = 13; 521CC, n = 2) and wild type controls (521TT, n = 13) completed a single oral dose pharmacokinetic study. The variability contributed by SLCO1B1 c.521 sequence variation to rosuvastatin (RVA) systemic exposure among our pediatric cohort was comparable to previous studies in adults. RVA concentration-time curve from 0-24 hours (AUC

Journal Title

Clin Transl Sci

Volume

13

Issue

3

First Page

628

Last Page

637

Comments

Grant support

• KL2TR002367/University of Kansas
• KL2 TR002367/TR/NCATS NIH HHS/United States

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Publisher's Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12749

Recommended Citation

Wagner JB, Abdel-Rahman S, Gaedigk A, et al. Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Transl Sci. 2020;13(3):628-637. doi:10.1111/cts.12749